CYCN - Cyclerion updates on clinical trial progress at webinar

At the webinar hosted by the company today, Cyclerion Therapeutics ([[CYCN]] -3.1%) shared the latest updates on its clinical programs for CY6463.The main programs in focus were the studies on Alzheimer's Disease with Vascular pathology (ADv), Cognitive Impairment Associated with Schizophrenia ("CIAS"), and Lactic Acidosis and Stroke-like episodes (MELAS).Having cleared the Investigational New Drug (IND) application for CY6463 in ADv, the company expects to start the enrollment for a 12-week Phase 2a clinical trial for ADv patients in mid-2021.Due to COVID-19, MELAS clinical trial is advancing at a slower pace than expected, Cyclerion said. The data from the exploratory 29-day open-label Phase 2a pilot study is now anticipated by year-end 2021.For CIAS, Cyclerion expects to initiate a Phase 1b signal-seeking study to evaluate the safety and near-term impact on disease-relevant biomarkers.The company also unveiled details on its newest development candidate, CY3018 for which IND-enabling studies are currently in progress.“We are using insights

For further details see:

Cyclerion updates on clinical trial progress at webinar